Board of Directors

 

Dr. Dragan Gabulovski, Business Development & Strategy, Chairman of the Board

Dr. Dragan Grabulovski is an advisor in pharmaceutical biotechnology at Grabulovski Consulting Services (CH). He was previously chief scientific officer and co-founder of Covagen AG, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014 with the participation of renowned investors such as GIMV, Edmond de Rothschild Investment Partners, Novartis Venture Fund and other prestigious funds. Dr. Grabulovski received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich (CH).

 

Dr. Robert Schier, Swisscanto, Investor Representative

Robert Schier joined Swissanto Invest at Zürcher Kantonalbank in 2018 as Member of Senior Management, Investment Director PE/VC. He has many years' experience in the healthcare and life sciences sector with background in biotech and as investment director and/or partner in various venture capital firms, such as Inventages Venture Capital and Seventure Partners.Robert Schier holds a degree in pharmacy from the University of Vienna and a PhD in biotechnology from the University of Natural Resources and Life Sciences, Vienna. He received the Keystone Award for Excellence in Research for his outstanding doctoral thesis, which he completed at the University of California, San Francisco. Dr Schier then completed an executive MBA programme at the European University Munich and is the author of several scientific publications and patents.

 

Dr. Nadine Geiser, Redalpine, Investor Representative

Nadine Geiser is Investment Manager at Redalpine. She studied biotechnology in Munich and Singapore before completing a PhD at ETH Zurich. She worked in Amsterdam for M Ventures, a corporate venture firm, and in the equity research department of Vontobel, an investment bank in Zurich, before ultimately joining Redalpine.

 

Dr. Urs Spitz, Board Member

CEO & President Biosynth Group since 2004, Senior Manager Mettler Toledo, Strategy Consultant at Bain & Co.
Education: Research Fellow at MIT, Ph. D. in organic Chemistry The University of Chicago, MSc in organic Chemistry and IT University of Zürich.

 

Dr. Christoph Esslinger, CSO, Board Member

Christoph Esslinger is the CSO and scientific founder of Memo Therapeutics AG and a pioneer of the discovery of therapeutic antibody candidates directly from human donors for immunotherapy of Alzheimer’s Disease and cancer. Prior to founding Memo Therapeutics AG he held senior positions at CT Atlantic AG, Neurimmune AG and in academia.

Christoph Esslinger holds a diploma in Technical Biology from University of Stuttgart and a PhD in Molecular Immunology from the Ludwig Institute for Cancer Research, Lausanne Branch and University of Lausanne.